Overview

A Study Evaluating the Safety and Efficacy of Multiple Treatment Combinations in Participants With Multiple Myeloma

Status:
Not yet recruiting

Trial end date:
2026-07-30

Target enrollment:

Participant gender:

Summary

CO43923 is a platform study that will evaluate the safety, efficacy, and pharmacokinetics (PK) of multiple treatment combinations in subsets of patients with multiple myeloma (MM). The study is designed with the flexibility to open new treatment substudies as new treatments become available. Information regarding the substudy opened is found below.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Hoffmann-La Roche

Treatments:

Lenalidomide